Actively Recruiting
International Collaborative Study to Develop the AJCC/UICC TNM Version-Ten for Nasopharyngeal Cancer
Led by The University of Hong Kong-Shenzhen Hospital · Updated on 2026-05-04
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
The University of Hong Kong-Shenzhen Hospital
Lead Sponsor
F
Fujian Cancer Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting an international, multicenter, prospective observational study to improve the staging and prediction of treatment outcomes for nasopharyngeal carcinoma (NPC). This study aims to enhance the current AJCC/UICC TNM Version-Nine staging system by incorporating anatomical parameters and integrating non-anatomical factors and molecular biomarkers like Epstein-Barr virus DNA levels. The study includes patients from both endemic and non-endemic regions to ensure the staging system is globally applicable and to provide detailed data for personalized treatment decisions. All patients enrolled will receive diagnosis and treatment according to the standard clinical practices at their respective participating centers. Patients diagnosed with NPC between October 2025 and September 2026 will be recruited and followed for five years. During this period, detailed information on clinical characteristics, imaging, molecular markers, treatment, and outcomes will be collected to analyze survival rates and patterns of treatment failure. Participants will undergo standard clinical evaluations, with experienced radiologists and oncologists assessing disease extent. Clinical outcomes, including overall survival and different types of treatment failure, will be recorded throughout the five-year follow-up. This comprehensive data collection aims to develop an improved TNM staging system to better stratify patient risk and guide personalized treatment strategies worldwide.
CONDITIONS
Brief Title
International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed nasopharyngeal carcinoma
- Diagnosed and treated between October 1, 2025 and September 30, 2026
- Adult participants aged 18 years and older
You will not qualify if you...
- Non-epithelial tumors of the nasopharynx, including lymphoma, sarcoma of soft tissue, bone or cartilage tumors, mucosal melanoma, and salivary type tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month
Participants undergo diagnosis of nasopharyngeal carcinoma using standard clinical practices including imaging and molecular marker assessment.
1 to 2 visits depending on diagnostic procedures
Duration - Up to 5 years
Participants who receive routine diagnosis and treatment are observed for outcomes including overall survival and failure-free survival at various sites.
Regular follow-up visits as part of standard care
Trial Site Locations
Total: 1 location
1
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China, 518009
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here